Tag: South Africa Business

  • Illicit GLP-1 Manufacturing Halted In Pretoria Raid

    The South African healthcare sector is facing intense regulatory scrutiny following a major raid on a compounding pharmacy in Pretoria. The South African Health Products Regulatory Authority (SAHPRA) targeted iDexis, trading as Sentra Pharmacy in Silverton. This joint operation with the South African Pharmacy Council (SAPC) highlights growing concerns over the booming local weight-loss market. The Raid On Sentra Pharmacy…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • African Vaccine Manufacturing Expansion Set For Biovac Site

    The South African vaccine producer Biovac has announced a major expansion of its Cape Town operations. This is a significant development in African vaccine manufacturing. This ambitious project receives significant backing from the European Investment Bank (EIB) Group and the International Finance Corporation (IFC). The new financing package will help Biovac develop end-to-end production capabilities. The primary focus will initially…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Dis-Chem’s Personalised Healthcare Strategy Redefines Retail

    South Africa’s healthcare retail sector is undergoing a bold transformation, with Dis-Chem leading the charge. In a strategic pivot from traditional marketing, Dis-Chem is embracing personalised healthcare to position itself as a fully integrated, tech-driven healthcare provider. This move redefines the pharmacy model, bringing together data, artificial intelligence (AI), and behavioural insights to deliver tailored experiences for every customer. Better…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Aspen Pharmacare Manufacturing Dispute Shrouded in Mystery

    ASPEN Pharmacare has issued a stark warning to investors. They are signalling a potential R2 billion plunge in core earnings for its 2025 financial year. This is due to the significant Aspen Pharmacare manufacturing dispute detailed this week. In a regulatory filing on Tuesday, Aspen alerted shareholders to emerging risks. It highlighted a “material contractual dispute” with an unnamed contract…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in